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Abstract
Background: Bulimia Nervosa (BN) is believed to be caused by an interaction of genetic and
environmental factors. Previous studies support the existence of a bulimia-related endophenotype
as well as disturbances in serotonin (5-HT) transmission. We studied serotonin transporter (SERT)
binding in BN, and to investigate the possibility of a SERT-related endophenotype for BN, did this
in a sample of female twins. We hypothesized clearly reduced SERT binding in BN women as
opposed to healthy women, and intermediate SERT binding in unaffected co-twins.
Methods: We studied 13 female twins with BN (9 with purging and 4 with non-purging BN) and
25 healthy women, including 6 healthy twin sisters of BN patients and 19 women from 10 healthy
twin pairs. [123I]ADAM, a selective SERT radioligand for single photon emission tomography (SPET)
imaging, was used to assess SERT availability in the midbrain and the thalamus.
Results: No differences in SERT binding were evident when comparing the BN women, their
unaffected co-twins and the healthy controls (p = 0.14). The healthy sisters of the BN patients and
the healthy control women had similar SERT binding in both brain regions. In a post hoc subgroup
analysis, the purging bulimics had higher SERT binding than the healthy women in the midbrain (p
= 0.03), but not in the thalamus.
Conclusion: Our finding of increased SERT binding in the midbrain in the purging BN women
raises the possibility that this subgroup of bulimics might differ in serotonergic function from the
non-purging ones. The similarity of the unaffected co-twins and the healthy controls doesn't
support our initial assumption of a SERT-related endophenotype for BN. Due to the small sample
size, our results need to be interpreted with caution and verified in a larger sample.
Background
Bulimia Nervosa (BN) is a common eating disorder that
predominantly affects young women. It is characterized
by body image distortions and episodes of excessive eat-
Published: 21 May 2007
BMC Psychiatry 2007, 7:19 doi:10.1186/1471-244X-7-19
Received: 21 September 2006
Accepted: 21 May 2007
This article is available from: http://www.biomedcentral.com/1471-244X/7/19
© 2007 Koskela et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Psychiatry 2007, 7:19 http://www.biomedcentral.com/1471-244X/7/19
Page 2 of 9
(page number not for citation purposes)
ing, followed by compensatory behaviors, such as strict
dieting, vomiting, laxative misuse or compulsive exercise
[1]. BN is often accompanied by disturbances of mood
and impulse control [2].
The neurotransmitter serotonin (5-HT), involved in the
regulation of eating behavior [3], may play a role in the
pathophysiology of BN. Subjects with symptomatic BN
show several abnormalities in 5-HT metabolism and func-
tion [4-9]. Both women with current BN and women who
have recovered from BN seem more vulnerable than
healthy control women to the mood lowering and the
binge precipitating effects of acute tryptophan depletion
[10,11]. A wide range of antidepressant medications are
effective in reducing binge and purge frequency [12,13].
It is uncertain whether the changes in 5-HT system in BN
are trait dependent (i.e., representing a predisposition to
an illness) or state dependent (i.e., resulting from changes
in nutritional status during an acute illness). There is
some evidence suggesting a bulimia-related endopheno-
type, such as premorbid anxiety symptoms [14] as well as
serotonergic alterations that remain after recovery
[11,15,16]. Evidence from family and twin studies sug-
gests a genetic contribution to the etiology of eating disor-
ders [17], but consistent evidence of genetic variation
specifically affecting serotonin metabolism disturbances
in BN is lacking. Twin samples offer an opportunity to
explore state and trait related differences, given that the
healthy twins share either all or half their segregating
genes with their affected co-twin, depending on whether
the twin pair is monozygotic (MZ) or dizygotic (DZ).
Moreover, twins are of the same age and have generally
similar childhood and adolescent experiences. Observed
differences between women with BN and their sisters are
likely due to state effects, whereas differences observed
between healthy twin sisters and unrelated controls
would be trait-related.
The recent developments of new radioligands for various
neurotransmitter systems for positron emission tomogra-
phy (PET) and single photon emission tomography
(SPET) imaging have enabled more direct, in vivo studies
of neurotransmitter dysfunction in different conditions.
Previous studies have suggested reduced availability of
brain serotonin transporters (SERTs) in BN [18] and Binge
Eating Disorder (BED) [19]. There are reports on
increased 5-HT1A-binding in BN [20] as well as on reduced
5-HT2A-binding in women who have recovered from BN
[16] and from bulimia-type Anorexia Nervosa [21].
Iodine 123-labeled 2-((2-((dimethylamino)methyl)phe-
nyl)thio)-5-iodophenylamine ([123I]ADAM) is a selective
radioligand for SPET imaging of SERTs. Its affinity to
SERTs is more than 1000-fold over its affinity to
dopamine transporters and norepinephrine transporters
[22]. Its binding is greatest [23,24] and least variable in a
test-retest setting in the midbrain and the thalamus [23],
and reaches a pseudoequilibrium at 4-6 h post injection
[23]. Its effective dose is similar to the other commonly
used radioligands [25,26]. We have previously created an
[123I]ADAM brain template and a predefined VOI (vol-
ume of interest) map for the automated registration and
analysis of the [123I]ADAM images [27].
The aim of this study was to (1) investigate whether the
finding of reduced SERT binding in subjects with BN
observed using the less selective radioligand [123I]β-CIT
[18] can be replicated with [123I]ADAM, and (2) to
explore the possible genetic background of BN by com-
paring [123I]ADAM binding to SERTs between subjects
with BN, their healthy co-twins and healthy controls. We
assumed that SERT transmission is a bulimia-related
endophenotype, i.e., a heritable quantitative trait that is
state-independent (manifest in the individual whether or
not illness is active), and found more often in unaffected
family members than in the general population. There-
fore, we hypothesized that SERT availability would be
clearly reduced in SERT rich brain areas in BN women
compared to unaffected women, and that the SERT avail-
ability of unaffected co-twins would be intermediate
between that of probands and healthy women.
Methods
Study participants
The study participants were recruited from FinnTwin16, a
population-based, longitudinal study including virtually
all Finnish twins born 1975-1979 and first studied at the
age of 16 [28]. At the age of 22-27 years, the 2545 female
twins were screened for eating disorders by self-report
questionnaire: 292 screen-positive women, their 130
female co-twins, and 210 screen-negative women were
then interviewed using a short version of the SCID-I inter-
view [29] (interview participation rate 85.2%) [30]. From
the interviews, we obtained lifetime diagnoses of ano-
rexia, bulimia, binge eating disorder, major depression
(MDD) and obsessive-compulsive disorder (OCD). All
women suffering from BN who were not on current sero-
tonergic medication (n = 13) as well as their female co-
twins were invited to participate in the [123I]ADAM study.
The DSM-IV diagnosis of bulimia nervosa of each case
detected was further confirmed with semi-structured
EATATE [31] and SSAGA interviews [32,33]. We chose to
also include two women recently recovered from BN in
this group on the basis of the evidence suggesting a trait
for BN.
Ten healthy, medication-free control female twin pairs
without bulimic symptoms were selected from the same
FinnTwin16 cohort and invited to participate in theBMC Psychiatry 2007, 7:19 http://www.biomedcentral.com/1471-244X/7/19
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[123I]ADAM study. They were also assessed with EATATE
and SSAGA interviews, which ruled out past or present
eating disorders and revealed one case with a former his-
tory of depression. We thus excluded her from our study.
Another healthy control was excluded due to an unsuc-
cessful [123I]ADAM injection.
In the present analysis, we have included:
1. 13 twin women fulfilling lifetime DSM IV criteria for BN,
including 7 women from discordant twin pairs (1 MZ pair
and 6 DZ pairs) and 6 women from concordant twin pairs
(2 MZ and 1 DZ).
2. 25 healthy twin women, including 6 healthy twin sisters
of the women with BN (1 MZ and 5 DZ) and 18 women
from 10 (5 MZ and 5 DZ female-female) healthy twin
pairs.
All the study subjects were free from psychotropic medica-
tion at the time of the study. 4 women with BN had previ-
ously been on selective serotonin reuptake inhibitor
(SSRI) medication, but had been drug-free for more than
1 year before the study.
The zygosity of all twin pairs was confirmed by genetic
blood marker studies using the highly polymorphic, mul-
tiple genetic marker set used in the Paternity testing labo-
ratory, National Public Health Institute, Helsinki,
Finland.
After complete description of the study procedures to the
subjects, written informed consent according to the Dec-
laration of Helsinki was obtained from all participants.
The Ethics Committees of Kuopio University Hospital and
Helsinki University Central Hospital approved the study.
Radiopharmaceutical
The radioligand [123I]ADAM [22] (MAP Medical Technol-
ogies Oy, Tikkakoski, Finland) was used for imaging of
brain serotonin transporters. Thirty minutes before its
intravenous injection, the subjects were given 400 mg of
potassium perchlorate orally to reduce [123I]-uptake in the
thyroid and the salivary glands. Injected radioactivity of
[123I]ADAM varied between 139-231 MBq.
SPET imaging and image reconstruction
The SPET scannings took place 5 hours after the injection
of [123I]ADAM with a Philips Picker Prism3000XP three-
headed gamma camera with ultra-high-resolution fan-
beam collimators (Philips Medical Systems, Cleveland,
OH, USA). The fan-beam focus of the collimator was 535
mm. We used 120 degree orbit in a stepwise mode and a
symmetrical energy window (159 keV; 20% wide, 143
keV-175 keV). The radius of rotation varied between 130-
160 mm, depending on the patient. The subjects' heads
were positioned with a crossed laser beam system to the
centre of rotation. Scans were acquired with a 128 × 128
matrix size using 120 projection angles (40 projections/
detector). The acquisition time was 45 s per projection
angle, resulting in an average of 20 kcts.
All reconstructions and image analyses were done on a
HERMES software system (Hermes Medical Solutions,
Stockholm, Sweden). The images were reconstructed iter-
atively (8 subsets with 6 iterations) using HOSEM (OS-
EM V5.201 by R. Larkin) and transverse slices were recon-
structed. Attenuation correction (Chang's first-order
approximation) was performed using the linear attenua-
tion correction (μ = 0.110 cm-1). Butterworth filter with
cut-off frequency of 1.2 cm-1 and order 15 was used for
post-filtering of the images.
Quantification of SERT availability
We have previously created a brain template with a prede-
fined volume of interest (VOI) map for [123I]ADAM
images using BRASS (Brain Registration and Analysis of
SPECT Studies) software (Hermes Medical Solutions,
Stockholm, Sweden) on a HERMES workstation [27]. We
used this template as a basis for automated registration
and realignment of the scans done for the subjects in the
study. The anatomically standardized (stereotactic)
images were used for automated VOI quantification. SERT
availability was assessed in VOIs of fixed size of the mid-
brain, the thalamus and the cerebellum, which was used
as a reference region [34] (Figure 1.). We chose to restrict
the data analyses to these regions on the basis of the pre-
vious data showing the greatest SERT binding and the
least test-retest variability in the midbrain and the thala-
mus [23]. The voxel size was 2 × 2 × 2 mm and the slice
separation 4 mm. Both the midbrain and the thalamus
VOIs were placed on 2 consecutive slices and consisted
alltogether of 94 (midbrain) and 386 (thalamus) voxels.
The cerebellum VOI was placed on 3 consecutive slices
and consisted of 1806 voxels. As the location of the mid-
brain activity varied a little between the subjects, more
than the location of the thalamus activity, we chose to
alter the position of the midbrain VOI manually, if it did
not seem correct. This was done without altering the size
of the VOI or the level (slice) on which the VOI was posi-
tioned by the automated procedure. All image reconstruc-
tions, registrations to the template and possible moving of
the midbrain VOIs were performed by a nuclear medicine
physician, who was blind to subject identity and diagno-
sis.
SERT binding was estimated by using the formula Specific
Binding Ratio (SBR) = (mean counts in the target area –
mean counts in cerebellum)/mean counts in cerebellum.
This model has been shown to correlate well with theBMC Psychiatry 2007, 7:19 http://www.biomedcentral.com/1471-244X/7/19
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graphical analysis with arterial plasma input for
[123I]ADAM-studies [35]. Half-life correction was done for
calculated SBR values.
Non-specific uptake was quantified by dividing the mean
counts/pixel of the cerebellar VOI by the injected activity.
Statistical analysis
The data were analyzed using the Stata software (release
8.2; Stata Corp., College Station, TX, USA). If needed, the
variables were log transformed to normalize their distri-
bution.
In accordance with our study objective of examining the
possible (genetic) differences of state and trait dependent
SERT binding, we distinguished 3 groups of subjects: BN
women, their healthy female co-twins and unrelated con-
trols. State differences would be revealed by observed dif-
ferences between BN women and their co-twins, whereas
any differences observed between healthy co-twins and
unrelated controls would be due to trait effects, given that
the healthy co-twins share childhood experiences as well
as at least half of their segregating genes with their affected
co-twin. Our sample size did not permit us to do analyses
by zygosity.
First, we compared all the twins as individuals. When
twins are analyzed as individuals rather than as pairs, the
observations and their error terms between members of a
pair may be correlated. Therefore, to account for individ-
uals nested within twin pairs, we used techniques derived
from hierarchical linear modeling to adjust for clustering
of twins within twin pairs. For comparison of the three
groups, i.e. the diseased subjects, their healthy co-twins
and the healthy control twin pairs we used one-way anal-
ysis of variance, and then appropriate two-group tests.
Multiple linear regression analyses were used to test the
effects of multiple explanatory variables on a response
variable. In Stata, the procedures SVYMEAN, SVYTEST and
SVYREG permit derivation of the proper standard errors,
variances, confidence intervals and P values, correcting for
dependency within a twin pair.
Second, we made within-pair comparisons to test the sig-
nificance of intra-pair differences in SERT binding in twin
pairs discordant for BN and in healthy twin pairs by using
the paired nonparametric Wilcoxon test. Third, we com-
pared the mean intrapair difference in SERT binding
between twin pairs discordant for BN and healthy control
twins by using the nonparametric Mann-Whitney U-test.
We also performed a post hoc analysis of the purging BN
women against all the healthy women combined. This
decision was based on the clinical observation that purg-
ing bulimia is often more severe in its course as compared
to non-purging type bulimia. Further post hoc analyses
were done on the effects of psychiatric co-morbidities on
study results.
Data are shown as mean ± standard deviation. P values
less than 0.05 were considered statistically significant.
Results
Demographic variables and behavioral assessments
The mean body mass indices (BMIs) and ages were similar
for the 13 women with BN, their twin sisters and the
healthy control twins (Table 1.) The mean age of onset of
bulimia was 18.3 y (SD: 2.9 y, range: 13 – 21 y) and its
mean duration was 6.5 y (SD: 4.4 y, range: 6 months – 14
y). Of the 2 subjects with lifetime BN, one had been
asymptomatic for 3 and the other for 5 years. 9 of the 13
bulimic individuals suffered from the purging subtype of
BN, and 4 were diagnosed with the non-purging subtype
of BN. Compensatory behaviors other than vomiting
included diuretics and Ipecac abuse, excessive exercise,
and fasting. 5 individuals had a past history of anorexic
symptoms, but had been free from anorectic symptoms
for more than 6 months prior to our study.
There was 1 case with present and 7 cases with past history
of major depressive disorder (MDD) in the BN group.
None of the healthy sisters or healthy control women suf-
fered from present MDD. One healthy control with a past
history of MDD was excluded from the study.
SERT availability in volumes of interest
The specific binding ratios of [123I]ADAM to SERTs in the
midbrain and the thalamus are shown in Table 2. SERT
binding was similar for the groups of BN probands, their
unaffected sisters and healthy control women in both the
midbrain (p = 0.14) and the thalamus (p = 0.85). The
unaffected sisters did not differ from the healthy controls
in neither the midbrain (p = 0.66) nor the thalamus (p =
The [123I]ADAM template (mean image of scans of 15 healthy  women) and the midbrain (left) and thalamus (right) volumes  of interest Figure 1
The [123I]ADAM template (mean image of scans of 15 healthy 
women) and the midbrain (left) and thalamus (right) volumes 
of interest.BMC Psychiatry 2007, 7:19 http://www.biomedcentral.com/1471-244X/7/19
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0.66), and therefore we combined these two groups of
healthy women. No significant differences were found in
comparison of the BN women and all the healthy women
combined (Table 3.). Removal of the 2 currently unsymp-
tomatic women from the group of probands did not affect
these results (data not shown). In a post hoc analysis, the
subgroup of purging bulimic women differed significantly
in their SERT binding from the healthy women in the
midbrain (p = 0.03) but not in the thalamus (p = 0.35)
(Table 3.).
In further post hoc analyses, we investigated the effect of
MDD and past history of AN on the results. SBRs in the
midbrain and the thalamus were similar for the subjects
with (n = 7) and without (n = 30) a history of MDD (in
the midbrain: SBRMDD 2.20 ± 0.22, SBRno-MDD 2.10 ± 0.30,
p = 0.38, and in the thalamus: SBRMDD 1.48 ± .28, SBRno-
MDD 1.42 ± .26, p = 0.63). Regarding past AN, the mean
SBRs for SERT binding were very similar for the BN
women with (n = 5) and without (n = 8) past history of
AN (in the midbrain: SBRAN 2.25 ± 0.26, SBRno-AN 2.21 ±
0.22, and in the thalamus: SBRAN 1.50 ± 0.28, SBRno-AN
1.42 ± 0.21). In multiple linear regression analysis, his-
tory of MDD or AN had no effect on the results, whereas
the effect of purging remained significant (Table 4).
In within-pair comparisons, there were no differences in
SBRs between a twin and her co-twin in either of the brain
regions in neither the group of twins discordant for BN (n
= 6 pairs) nor the healthy twin pairs (n = 9 pairs). The
means of intrapair differences for SBRs (SBR of twin 1-SBR
of twin 2 in a given area) were also similar for the discord-
ant twin pairs and the healthy control twin pairs in both
the midbrain and the thalamus regions. Within-pair com-
parisons were not done for the pairs discordant for purg-
ing lifetime BN as we had only two such pairs.
SERT binding in the cerebellum (i.e., non-specific uptake)
did not differ between the groups (98.99 ± 17.53 counts/
pixel/kBq for the subjects with lifetime BN, 93.38 ± 21.42
counts/pixel/kBq for the healthy co-twins and 96.52 ±
15.26 counts/pixel/kBq for the healthy controls, p =
0.73).
Discussion
In this study, we examined the binding of a SERT-specific
radioligand [123I]ADAM to the midbrain and the thala-
mus of women with bulimia nervosa, their healthy female
co-twins and healthy controls. Against our initial hypoth-
esis, we found no differences in SERT binding between the
three study groups. However, in a post hoc analysis we
observed increased SERT binding in the midbrain in the
purging BN women. Our work extends the previous liter-
ature on the role of serotonergic pathways in the etiology
of BN[36] and suggest differences in SERT function
between the purging and the non-purging BN women.
Our findings do not support the existence of a bulimia-
related endophenotype.
The involvement of serotonergic system in BN has been
suggested in a number of studies. Examples include
blunted plasma hormonal response to drugs with 5-HT
activity [5], worsening of symptoms after dietary deple-
tion of tryptophan (precursor of 5-HT) [10], the beneficial
effect of antidepressant medications in BN [12,13], and
differences found in brain PET- and SPET-studies in SERTs
[18] and 5-HT1A-receptors [20]. Furthermore, some dis-
turbances of serotonergic system, such as vulnerability to
the effects of tryptophan depletion [11] and elevation of
cerebrospinal fluid concentration of 5-HT metabolite 5-
hydroxyindolacetic acid (5-HIAA) [15], seem to persist
after recovery. Alterations after recovery have also been
found in the imaging studies of 5HT2A-receptors [16].
There are several possible explanations to our failure to
find differences of SERT binding between the whole group
of bulimics and the healthy subjects. First, there may be
alterations of SERT function in other brain regions than
were investigated in our study. Some existing data from
functional magnetic resonance imaging studies suggest
alterations in the lateral fusiform gyrus, the inferior pari-
etal cortex, and the lateral prefrontal cortex [37]. PET and
SPET studies with 5-HT1A and 5-HT2A ligands have found
changes in the the frontal, parietal and cingulate areas
[36]. As the binding of [123I]ADAM is scant and less relia-
ble in these regions [23], we did not investigate them in
our study. Second, the disturbances of serotonergic func-
tion in BN may not be found in SERTs, but instead in
other parts of the serotonergic system. Two previous stud-
ies have suggested alterations in 5-HT2A and 5-HT1A-recep-
tors [20,21]. Even though the SSRIs have been shown to
be useful in the treatment of BN [38], it does not necessar-
ily indicate a disturbance of SERT function in BN, as the
mechanism of action of the SSRIs is not believed to be
Table 1: Study subjects' ages and BMIs
Bulimics (n = 13) Twin-sisters (n = 6) Controls (n = 18) P*
BMI (kg/m2) 22.9 ± 3.2 23.6 ± 3.2 22.2 ± 3.5 0.68
Age (years) 24.8 ± 1.7 24.8 ± 2.1 25.3 ± 1.7 0.81
*Significant differences between the groups were calculated using ANOVA: p-values were corrected for clustered sampling.BMC Psychiatry 2007, 7:19 http://www.biomedcentral.com/1471-244X/7/19
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direct effect on SERT or increased synaptic 5-HT [39].
Desensitization of somatodendritic 5-HT1A autoreceptors
in the midbrain raphe nucleus is one suggested mecha-
nism; this would increase 5-HT in critical brain regions
and at key receptor subtypes [40-43]. Third, there is also a
possibility of impairments outside but in connection to
the serotonergic system. According to one theory, 5-HT
acts as a modulator in the homeostasis between
dopamine, noradrenalin and GABA. Serotonergic drugs
might help reinstate the homeostasis of this system [44].
Another suggested mechanism of action of the SSRIs is the
potentiation of neurogenesis [45].
There is also the possibility that the inclusion of the two
currently unsymptomatic BN women diluted the differ-
ences between the probands and the healthy women.
Their inclusion was based on our initial hypothesis of a
bulimia-related endophenotype. As we later observed, our
results on the unaffected co-twins do not support the idea
of a SERT associated endophenotype for BN. However,
removal of these two women from the probands did not
change our findings.
It is also possible that BN may in fact include biologically
distinct subgroups. Purging bulimics have been found to
differ from non-purging ones in certain personality varia-
bles (e.g. lower self-directedness, organization, personal
standards, and higher novelty seeking) [46]. Our results
point towards a difference of SERT function between these
two subgroups, given that only the subjects with a purg-
ing-subtype of BN differed significantly from the healthy
subjects in the midbrain SBRs. As this is a finding of a post
hoc analysis and made in a small study sample, it needs to
be confirmed in other studies.
There are some important differences between the present
study and the previous study on SERT binding in BN [18].
The radioligand previously used was [123I]β-CIT, which
binds to DATs and NETs as well as to SERTs [47-49], leav-
ing a possibility that its binding to NETs in the thalamus
has affected the findings. Another difference lies at the
study groups. It is possible that our BN cases, identified
from a population-based twin cohort, were different to
the clinic-based cases in the previous study. Thus, treat-
ment seeking characteristics, disease severity and other
differences between the study groups may to a point
explain the differences between these two studies. Also,
the exclusion of cases with psychotropic medication from
our study probably shifts the balance towards clinically
less complex cases.
In our study, SERT binding was similar in the healthy co-
twins of the bulimics and the other healthy women. It is
not known whether the previously reported alterations of
5-HT function after recovery [11,15,16] represent "scar-
ring" caused by BN or a disturbance of 5-HT function that
is present before the actual symptoms, predisposing a sub-
ject for BN. The reported premorbid anxiety symptoms
[14] suggest presence of vulnerability for BN and the evi-
dence from family and twin studies suggests a genetic con-
tribution to etiology of eating disorders [17]. If such a
genetic trait (i.e., endophenotype) exists in SERT function,
it should be evident in the unaffected co-twins of the BN
probands. Our finding of similarity of SERT binding
between the co-twins and the other healthy women is
against our initial hypothesis and does not support the
existence of a SERT-related trait for BN. However, the
small number of the unaffected co-twins reduces the reli-
ability of this conclusion and also prevented analyses sep-
arately by zygosity. The number of unaffected co-twins of
the purging bulimics (n = 2) was even smaller: therefore,
we cannot make assumptions on whether the observed
increase in SERT binding in the purging BN women is a
state- or trait-related increase in SERT binding.
Table 3: SBRs: Comparison of all healthy women with all BN women and the subgroup of purging BN women
Women with lifetime BN (n = 13) All healthy women (n = 24) Women with purging BN (n = 9) P* P**
Midbrain 2.23 ± 0.22 2.06 ± 0.30 2.26 ± 0.19 0.08 0.03
Thalamus 1.45 ± 0.23 1.42 ± 0.28 1.50 ± 0.25 0.73 0.45
* Women with lifetime BN vs. all healthy women. t-test, correction for dependency within twin pairs
** Women with lifetime purging BN vs. all healthy subjects. t-test, correction for dependency within twin pairs
Table 2: SBRs for women with lifetime BN, their healthy co-twins and healthy control women
Women with lifetime BN (n = 13) Healthy co-twins (n = 6) Healthy control women (n = 18) P*
Midbrain 2.23 ± 0.22 2.02 ± 0.29 2.07 ± 0.31 0.21
Thalamus 1.45 ± 0.23 1.38 ± 0.25 1.43 ± 0.29 0.86
*ANOVA, correction for dependency within twin pairsBMC Psychiatry 2007, 7:19 http://www.biomedcentral.com/1471-244X/7/19
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Our results differed from the initial hypothesis also in the
direction of the difference in SERT binding. Our initial
hypothesis was reduced SERT binding in BN: however,
what we found was increased SERT binding in the purging
probands. Many studies suggest reduced 5-HT transmis-
sion in BN [4-10,16,18]. Also in many (but not all) SPET
and PET studies, reduced SERT binding has been inter-
preted to indicate reduced 5-HT function. However, this
assumption may not necessarily be true. Theoretically,
reduced intrasynaptic 5-HT could lead to increased bind-
ing of the radioligand due to 1) less competition for the
binding sites or 2) compensatory increase in the amount
of SERT on the nerve terminals. Alternatively, reduced 5-
HT could reduce SERT binding if the amount of SERTs on
nerve terminals is reduced due to increased internaliza-
tion of SERTs [50]. Recent PET studies with the SERT lig-
and  11C-DASB have assessed the effects of artificial
alterations of intrasynaptic 5-HT. The findings to date are
inconsistent, with reports of either decreased [51] or
unchanged [52] SERT binding after decrease in intrasyn-
aptic 5-HT or decreased binding after increase in intrasyn-
aptic 5-HT [53]. The true nature of the relationship of
intrasynaptic 5-HT concentration and SERT binding is
thus yet to be discovered. Furthermore, not only the
amount of intrasynaptic 5-HT but also disease specific
alterations in number and affinity of SERTs can affect
SERT binding. Therefore, we don't really know the true
interpretation of our findings: we can only state that we
found a difference in a direction opposite from our origi-
nal hypothesis.
There are some limitations to our study. Our sample size
is smaller than we initially aimed for. Even though we
screened thousands of twins, the number of BN probands
was smaller than we expected. The presence of three con-
cordant pairs also reduced the number of the unaffected
co-twins, limiting our ability to make conclusions on the
endophenotype concept. One factor that clearly reduced
the number of our cases was the exclusion of subjects with
antidepressant medication. We acknowledge the limited
power of our study and the considerable probalility of
both type one (due to multiple comparisons) and type
two (due to small sample size) errors. Furthermore, the
inclusion of subjects with past histories of MDD and AN
are possible confounds. These conditions often co-exist
and exclusion of probands with past history of MDD or
AN would have made our study sample even smaller.
However, in post hoc analyses, neither of these conditions
had effect on our results.
We did not control for phase of menstrual cycle, which
has been implicated as source of variation in SERT bind-
ing [54]. However, a recent study with [123I]-β-CIT found
no such effect [55]. On the other hand, we could fully
exclude variation due to sex and age by including only
females within a narrow age-range.
The radiotracer [123I]ADAM might have some properties
that affect its usefulness in SERT imaging. The reported
intra-subject test-retest variability of [123I]ADAM binding
is 13% in midbrain and 16% in thalamus, which is, how-
ever, of the same magnitude as for other SERT SPET lig-
ands [23]. There is also a report on lipophilic metabolites
of [123I]ADAM [35], which, if present, might also affect
our findings. We also can not exclude the possibility of
different metabolism of [123I]ADAM between patients and
healthy subjects as we did not do blood screening of its
metabolism. The cerebellar activity, which mostly repre-
sents non-spesific binding of [123I]ADAM, did not differ
between the groups.
Our template based realignment and fitting procedure is
objective and repeatable, but may lead to some small
errors of VOI placement and also dilute or emphasize
some effects. However, this method was most suitable for
our study as Magnetic Resonance Imaging (MRI) – based
VOI definition was prevented by some of our subjects hav-
ing contraindications for MRI. We tried to minimize the
VOI placement errors by manually moving the midbrain-
Table 4: Multiple regression analysis examining the relationship of SERT binding with purging BN and past histories of Major 
Depression and Anorexia Nervosa
MIDBRAIN: R2 = 0.10, F(3,17) = 3.92, p = 0.03 β S.E. of β p-value
Purging BN -.22 .09 .02
History of major depression .08 .10 0.44
History of AN -.08 .09 0.38
THALAMUS: R2 = 0.03, F(3,17) = 1.02, p = 0.41 β S.E. of β p-value
Purging BN -.10 .06 0.14
History of major depression .02 .09 0.80
History of AN -.04 .12 0.72
Correction for dependency between twin pairs done forBMC Psychiatry 2007, 7:19 http://www.biomedcentral.com/1471-244X/7/19
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VOI of fixed size within the fixed brain level, when neces-
sary.
In summary, our results do not support the initial
assumption of decreased SERT binding in BN or the exist-
ence of a SERT-related endophenotype for BN. Instead,
the increased SERT binding in the midbrain of purging
bulimics observed in this study suggests that the involve-
ment of SERT function in this type of BN is stronger than
in non-purging BN and differs from healthy subjects.
However, due to small sample size and confounding fac-
tors our results need to be taken with caution and verified
in larger samples of clinical BN cases.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
AK carried out and analysed the SPET studies, performed
statistical analyses and was the main author of the manu-
script.
AK-R and ES participated by planning the study design, in
selecting the study subjects, and doing the psychiatric
assessments, and by commenting on, revising and
approving the manuscript.
TK participated by planning the SPET protocol and quan-
tification of the SPET studies, commenting on, revising
and approving the manuscript.
JK participated by collecting the Finnish Twin Cohort
data, in planning of the BN study, and by commenting on,
revising and approving the manuscript.
AA participated by planning the SPET protocol, comment-
ing on, revising and approving the manuscript.
AR participated by planning the study design, comment-
ing on, revising and approving the manuscript.
All the authors have read and approved the final manu-
script.
Acknowledgements
The authors thank Dr. Markus Diemling from Hermes Medical Solutions, 
Stockholm, Sweden, for the help in the creation of [123I]ADAM template, 
Mr. Timo Lukkarinen for providing the MR images, Erjastiina Heikkinen for 
assisting in scheduling the study subjects, and all the twins who participated 
this study.
This work was supported by the USPHS National Institute of Alcohol 
Abuse and Alcoholism (AA08315, AA12502), the European Union Fifth 
Framework Program (QLRT-1999-00916, QLG2-CT-2002-01254), Acad-
emy of Finland grants, the Academy of Finland Center of Excellence in 
Complex Disease Genetics, and Helsinki University Central Hospital grants 
and A.K. by Research Foundation of the Orion Corporation.
References
1. American Psychiatric Association: DSM IV: diagnostic and statistical
manual of mental disorders 4th edition. Washington, DC, American
Psychiatric Association; 1994. 
2. Kaltiala-Heino R, Rissanen A, Rimpela M, Rantanen P: Bulimia and
impulsive behaviour in middle adolescence.  Psychother Psycho-
som 2003, 72:26-33.
3. Leibowitz SF, Alexander JT: Hypothalamic serotonin in control
of eating behavior, meal size, and body weight.  Biol Psychiatry
1998, 44:851-864.
4. Goldbloom DS, Hicks LK, Garfinkel PE: Platelet serotonin uptake
in bulimia nervosa.  Biol Psychiatry 1990, 28:644-647.
5. Goldbloom DS, Garfinkel PE, Katz R, Brown GM: The hormonal
response to intravenous 5-hydroxytryptophan in bulimia
nervosa.  J Psychosom Res 1996, 40:289-297.
6. Jimerson DC, Lesem MD, Kaye WH, Brewerton TD: Low serot-
onin and dopamine metabolite concentrations in cerebrospi-
nal fluid from bulimic patients with frequent binge episodes.
Arch Gen Psychiatry 1992, 49:132-138.
7. Jimerson DC, Wolfe BE, Metzger ED, Finkelstein DM, Cooper TB,
Levine JM: Decreased serotonin function in bulimia nervosa.
Arch Gen Psychiatry 1997, 54:529-534.
8. Kaye WH, Ballenger JC, Lydiard RB, Stuart GW, Laraia MT, O'Neil P,
Fossey MD, Stevens V, Lesser S, Hsu G: CSF monoamine levels in
normal-weight bulimia: evidence for abnormal noradrener-
gic activity.  Am J Psychiatry 1990, 147:225-229.
9. Kaye W, Gendall K, Strober M: Serotonin neuronal function and
selective serotonin reuptake inhibitor treatment in anorexia
and bulimia nervosa.  Biol Psychiatry 1998, 44:825-838.
10. Kaye WH, Gendall KA, Fernstrom MH, Fernstrom JD, McConaha
CW, Weltzin TE: Effects of acute tryptophan depletion on
mood in bulimia nervosa.  Biol Psychiatry 2000, 47:151-157.
11. Smith KA, Fairburn CG, Cowen PJ: Symptomatic relapse in
bulimia nervosa following acute tryptophan depletion.  Arch
Gen Psychiatry 1999, 56:171-176.
12. Mitchell JE, Raymond N, Specker S: A review of the controlled tri-
als of pharmacotherapy and psychotherapy in the treatment
of bulimia nervosa.  Int J Eat Disord 1993, 14:229-247.
13. Walsh BT: Psychopharmacologic treatment of bulimia ner-
vosa.  J Clin Psychiatry 1991, 52(Suppl):34-38.
14. Kaye WH, Bulik CM, Thornton L, Barbarich N, Masters K: Comor-
bidity of anxiety disorders with anorexia and bulimia ner-
vosa.  Am J Psychiatry 2004, 161:2215-2221.
15. Kaye WH, Greeno CG, Moss H, Fernstrom J, Fernstrom M, Lilenfeld
LR, Weltzin TE, Mann JJ: Alterations in serotonin activity and
psychiatric symptoms after recovery from bulimia nervosa.
Arch Gen Psychiatry 1998, 55:927-935.
16. Kaye WH, Frank GK, Meltzer CC, Price JC, McConaha CW, Crossan
PJ, Klump KL, Rhodes L: Altered serotonin 2A receptor activity
in women who have recovered from bulimia nervosa.  Am J
Psychiatry 2001, 158:1152-1155.
17. Bulik CM, Sullivan PF, Wade TD, Kendler KS: Twin studies of eat-
ing disorders: a review.  Int J Eat Disord 2000, 27:1-20.
18. Tauscher J, Pirker W, Willeit M, de Zwaan M, Bailer U, Neumeister
A, Asenbaum S, Lennkh C, Praschak-Rieder N, Brucke T, Kasper S:
[123I] beta-CIT and single photon emission computed tom-
ography reveal reduced brain serotonin transporter availa-
bility in bulimia nervosa.  Biol Psychiatry 2001, 49:326-332.
19. Kuikka JT, Tammela L, Karhunen L, Rissanen A, Bergstrom KA,
Naukkarinen H, Vanninen E, Karhu J, Lappalainen R, Repo-Tiihonen E,
Tiihonen J, Uusitupa M: Reduced serotonin transporter binding
in binge eating women.  Psychopharmacology 2001, 155:310-314.
20. Tiihonen J, Keski-Rahkonen A, Lopponen M, Muhonen M, Kajander J,
Allonen T, Nagren K, Hietala J, Rissanen A: Brain serotonin 1A
receptor binding in bulimia nervosa.  Biol Psychiatry 2004,
55:871-873.
21. Bailer UF, Price JC, Meltzer CC, Mathis CA, Frank GK, Weissfeld L,
McConaha CW, Henry SE, Brooks-Achenbach S, Barbarich NC, Kaye
WH: Altered 5-HT(2A) receptor binding after recovery from
bulimia-type anorexia nervosa: relationships to harm avoid-
ance and drive for thinness.  Neuropsychopharmacology 2004,
29:1143-1155.BMC Psychiatry 2007, 7:19 http://www.biomedcentral.com/1471-244X/7/19
Page 9 of 9
(page number not for citation purposes)
22. Oya S, Choi SR, Hou C, Mu M, Kung MP, Acton PD, Siciliano M, Kung
HF:  2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophe-
nylamine (ADAM): an improved serotonin transporter lig-
and.  Nucl Med Biol 2000, 27:249-254.
23. Catafau AM, Perez V, Penengo MM, Bullich S, Danus M, Puigdemont
D, Corripio I, Pascual C, Perich X, Alvarez E: SPECT of serotonin
transporters using 123I-ADAM: optimal imaging time after
bolus injection and long-term test-retest in healthy volun-
teers.  J Nucl Med 2005, 46:1301-1309.
24. Erlandsson K, Sivananthan T, Lui D, Spezzi A, Townsend CE, Mu S,
Lucas R, Warrington S, Ell PJ: Measuring SSRI occupancy of
SERT using the novel tracer [123I]ADAM: a SPECT valida-
tion study.  Eur J Nucl Med Mol Imaging 2005, 32:1329-1336.
25. Kauppinen TA, Bergström KA, Heikman P, Hiltunen J, Ahonen AK:
Biodistribution and radiation dosimetry of (123-I)-ADAM in
healthy human subjects: preliminary results.  Eur J Nucl Med
Mol Imaging 2003, 30:132-136.
26. Newberg AB, Plossl K, Mozley PD, Stubbs JB, Wintering N, Udeshi M,
Alavi A, Kauppinen T, Kung HF: Biodistribution and imaging with
(123)I-ADAM: a serotonin transporter imaging agent.  J Nucl
Med 2004, 45:834-841.
27. Kauppinen TA, Koskela A, Diemling M, Keski-Rahkonen A, Sihvola E,
Ahonen A: Comparison of manual and automated quantifica-
tion methods of [123I]ADAM.  Nuklearmedizin 2005, 44:205-212.
28. Kaprio J, Pulkkinen L, Rose RJ: Genetic and environmental fac-
tors in health-related behaviors: studies on Finnish twins and
twin families.  Twin Res 2002, 5:366-371.
29. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Inter-
view for DSM-IV Axis I and Axis II Disorders New York.: Biometrics
Research Department, New York State Psychiatric Institute; 1997. 
30. Keski-Rahkonen A, Sihvola E, Raevuori A, Kaukoranta J, Bulik CM,
Hoek HW, Rissanen A, Kaprio J: Reliability of self-reported eat-
ing disorders: Optimizing population screening.  Int J Eat Disord
2006, 39:754-62.
31. Anderluh MB, Tchanturia K, Rabe-Hesketh S, Treasure J: Childhood
obsessive-compulsive personality traits in adult women with
eating disorders: defining a broader eating disorder pheno-
type.  Am J Psychiatry 2003, 160:242-247.
32. Bucholz KK, Cadoret R, Cloninger CR, Dinwiddie SH, Hesselbrock
VM, Nurnberger JI Jr, Reich T, Schmidt I, Schuckit MA: A new, semi-
structured psychiatric interview for use in genetic linkage
studies: a report on the reliability of the SSAGA.  J Stud Alcohol
1994, 55:149-158.
33. Wade T, Heath AC, Abraham S, Treloar SA, Martin NG, Tiggemann
M: Assessing the prevalence of eating disorders in an Austral-
ian twin population.  Aust N Z J Psychiatry 1996, 30:845-851.
34. Backstrom I, Bergstrom M, Marcusson J: High affinity [3H]parox-
etine binding to serotonin uptake sites in human brain tissue.
Brain Res 1989, 486:261-268.
35. Frokjaer VG, Pinborg LH, Madsen J, deNijs R, Knudsen GM: Evalua-
tion of the Serotonin Transporter Ligand [I-123]ADAM for
SPECT Studies in Humans [abstract].  In Annales Universitatis
Turkuensis D 660: Turku PET symposium 2005 Edited by: Nyman MJ,
Oikonen V, Turiceanu M, Scheinen H. Turku, Turun Yliopisto;
2005:78. 
36. Kaye WH, Frank GK, Bailer UF, Henry SE, Meltzer CC, Price JC,
Mathis CA, Wagner A: Serotonin alterations in anorexia and
bulimia nervosa: new insights from imaging studies.  Physiol
Behav 2005, 85:73-81.
37. Uher R, Murphy T, Friederich HC, Dalgleish T, Brammer MJ, Giampi-
etro V, Phillips ML, Andrew CM, Ng VW, Williams SC, Campbell IC,
Treasure J: Functional neuroanatomy of body shape percep-
tion in healthy and eating-disordered women.  Biol Psychiatry
2005, 58:990-997.
38. Walsh BT: Fluoxetine treatment of bulimia nervosa.  J Psycho-
som Res 1991:33-40.
39. Vaswani M, Linda FK, Ramesh S: Role of selective serotonin
reuptake inhibitors in psychiatric disorders: a comprehen-
sive review.  Prog Neuropsychopharmacol Biol Psychiatry 2003,
27:85-102.
40. Fuller RW: Pharmacologic modification of serotonergic func-
tion: drugs for the study and treatment of psychiatric and
other disorders.  J Clin Psychiatry 1986, 47(Suppl):4-8.
41. Gonzalez-Heydrich J, Peroutka SJ: Serotonin receptor and
reuptake sites: pharmacologic significance.  J Clin Psychiatry
1990, 51(Suppl):5-12.
42. Goodwin GM: How do antidepressants affect serotonin recep-
tors? The role of serotonin receptors in the therapeutic and
side effect profile of the SSRIs.  J Clin Psychiatry 1996, 57(Suppl
4):9-13.
43. Stahl SM: Mechanism of action of serotonin selective reuptake
inhibitors. Serotonin receptors and pathways mediate ther-
apeutic effects and side effects.  J Affect Disord 1998, 51:215-235.
44. Petty F, Davis LL, Kabel D, Kramer GL: Serotonin dysfunction dis-
orders: a behavioral neurochemistry perspective.  J Clin Psychi-
atry 1996, 57(Suppl 8):11-16.
45. Coyle JT, Duman RS: Finding the intracellular signaling path-
ways affected by mood disorder treatments.  Neuron 2003,
38:157-160.
46. Reba L, Thornton L, Tozzi F, Klump KL, Brandt H, Crawford S, Crow
S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, Keel P, LaVia M,
Mitchell J, Strober M, Woodside DB, Rotondo A, Berrettini WH,
Kaye WH, Bulik CM: Relationships between features associ-
ated with vomiting in purging-type eating disorders.  Int J Eat
Disord 2005, 38:287-294.
47. Innis R, Baldwin R, Sybirska E, Zea Y, Laruelle M, al-Tikriti M, Charney
D, Zoghbi S, Smith E, Wisniewski G: Single photon emission com-
puted tomography imaging of monoamine reuptake sites in
primate brain with [123I]CIT.  Eur J Pharmacol 1991,
200:369-370.
48. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-
Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer
JL: SPECT imaging of dopamine and serotonin transporters
with [123I]beta-CIT: pharmacological characterization of
brain uptake in nonhuman primates.  Synapse 1993, 13:295-309.
49. Neumeyer JL, Tamagnan G, Wang S, Gao Y, Milius RA, Kula NS, Bal-
dessarini RJ: N-substituted analogs of 2 beta-carbomethoxy-3
beta-(4'-iodophenyl)tropane (beta-CIT) with selective affin-
ity to dopamine or serotonin transporters in rat forebrain.  J
Med Chem 1996, 39:543-548.
50. Ramamoorthy S, Blakely RD: Phosphorylation and sequestration
of serotonin transporters differentially modulated by psy-
chostimulants.  Science 1999, 285:763-766.
51. Milak MS, Ogden RT, Vinocur DN, Van Heertum RL, Cooper TB,
Mann JJ, Parsey RV: Effects of tryptophan depletion on the bind-
ing of [11C]-DASB to the serotonin transporter in baboons:
response to acute serotonin deficiency.  Biol Psychiatry 2005,
57:102-106.
52. Talbot PS, Frankle WG, Hwang DR, Huang Y, Suckow RF, Slifstein M,
Abi-Dargham A, Laruelle M: Effects of reduced endogenous 5-
HT on the in vivo binding of the serotonin transporter radi-
oligand 11C-DASB in healthy humans.  Synapse 2005,
55:164-175.
53. Lundquist P, Roman M, Syvanen S, Hartvig P, Blomquist G, Hamma-
rlund-Udenaes M, Langstrom B: Effect on [(11)C]DASB binding
after tranylcypromine-induced increase in serotonin concen-
tration: Positron emission tomography studies in monkeys
and rats.  Synapse 2007, 61:440-449.
54. Wihlback AC, Sundstrom Poromaa I, Bixo M, Allard P, Mjorndal T,
Spigset O: Influence of menstrual cycle on platelet serotonin
uptake site and serotonin2A receptor binding.  Psychoneuroen-
docrinology 2004, 29:757-766.
55. Best SE, Sarrel PM, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM,
Seibyl JP, Innis RB, van Dyck CH: Striatal dopamine transporter
availability with [123I]beta-CIT SPECT is unrelated to gen-
der or menstrual cycle.  Psychopharmacology 2005, 183:181-189.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-244X/7/19/pre
pub